A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Guselkumab
DRUG: Risankizumab

Sponsor

Janssen Research & Development, LLC